Search clinical trials for: Pramipexole

Total 139 results

Bennett, James P., Jr., M.D., Ph.D.
University of Pittsburgh; University of Nebraska

Temporarily not available

Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

Amyotrophic Lateral Sclerosis
Boehringer Ingelheim

Completed

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

Parkinson Disease
Boehringer Ingelheim

Completed

Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

Restless Legs Syndrome

Switzerland
University of Toronto
Michael J. Fox Foundation for Parkinson's Research

Unknown

L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease

Parkinson's Disease

Canada
Dr. D McIntosh & Dr. K Kjernisted Clinical Research...
AstraZeneca

Completed

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

Bipolar Depression

United States, Canada
Astellas Pharma Korea, Inc.

Recruiting

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Korea, Republic of
AstraZeneca

Terminated

GALLANT 7 Tesaglitazar Add-on to Sulphonylurea

Type 2 Diabetes

France, Korea, Republic of, South Africa, Spain, United Kingdom, Vietnam, Norway, Israel, Philippines, Australia
Desitin Arzneimittel GmbH
FGK Clinical Research GmbH

Completed

Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists (PIVICOG-PD)

Idiopathic Parkinson's Disease

Germany
GlaxoSmithKline

Completed

Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors

Obsessive-Compulsive Disorder

United Kingdom
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients (RLS)

Idiopathic Restless Legs Syndrome

United States, Spain, Finland, Italy, Germany, Sweden, Austria, Netherlands, United Kingdom
Ottawa Hospital Research Institute

Completed

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA)

Breast Cancer | Prostate Cancer | Metastasis

Canada
Huashan Hospital
Boehringer Ingelheim

Completed

The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease

Idiopathic Parkinson's Disease

China
Stanford University
National Alliance for Research on Schizophrenia and Depression

Terminated

Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole

Depression

United States
Boehringer Ingelheim

Completed

Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)

Restless Legs Syndrome

Finland
Boehringer Ingelheim

Completed

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

Restless Legs Syndrome

United States
Vanderbilt University Medical Center
United States Department of Defense

Completed

Social Decision Making in Parkinson's Disease

Parkinson Disease

United States
University of Oxford

Completed

Pramipexole and Emotional Processing (PEP)

Emotions | Motivation | Dopamine | Reward

United Kingdom
Boehringer Ingelheim

Completed

Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)

Restless Legs Syndrome

China
Boehringer Ingelheim

Completed

Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD

Parkinson Disease

Austria, Czech Republic, Hungary, India, Italy, Korea, Republic of, Philippines, Poland, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

Restless Legs Syndrome

United States
Boehringer Ingelheim

Completed

Profile of Depressive Symptoms in Parkinsons Disease

Depression | Parkinson Disease

Netherlands, Germany, Italy, Switzerland, Austria, France, Spain, United Kingdom
Mauro Manconi
University Hospital Inselspital, Berne; Cardiocentro Ticino

Completed

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome (AUTOREST)

Restless Legs Syndrome

Switzerland
Boehringer Ingelheim

Completed

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

Parkinson Disease
Boehringer Ingelheim

Completed

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

Parkinson Disease

United States
Region Skane
Lund University

Recruiting

Pramipexole for Anhedonic Depression (PRIME-PRAXOL)

Depression | Anhedonia | Psychiatric Disorders Mood

Sweden
Massachusetts General Hospital
European Leukodystrophy Association

Recruiting

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

Restless Legs Syndrome | Adrenoleukodystrophy

United States, Netherlands
Knopp Biosciences
Biogen

Terminated

Phase 3 Extension Study of Dexpramipexole in ALS (ENVISION)

Amyotrophic Lateral Sclerosis

United States, United Kingdom, Netherlands, Spain, Belgium, Germany, Australia, Sweden, France, Ireland, Canada
Boehringer Ingelheim

Completed

Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Restless Legs Syndrome
Boehringer Ingelheim

Completed

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

Parkinson Disease
Boehringer Ingelheim

Completed

Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)

Restless Legs Syndrome

Austria, Belgium, Finland, Germany, Ireland, Netherlands, Slovakia, Spain, United Kingdom
Boehringer Ingelheim

Completed

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

Parkinson Disease

United States, Austria, Czech Republic, Finland, France, Germany, Hungary, India, Japan, Malaysia, Netherlands, Russian Federation, Slovakia, Taiwan, Ukraine
Kissei Pharmaceutical Co., Ltd.

Completed

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease

Parkinson Disease
Boehringer Ingelheim

Completed

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

Depression | Parkinson Disease

Austria, Finland, France, Germany, Italy, Netherlands, Norway, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine
Boehringer Ingelheim

Completed

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

Parkinson Disease

United States
Seoul National University Hospital

Unknown

Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)

Parkinson's Disease

Korea, Republic of
Areteia Therapeutics

Recruiting

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) (EXHALE-3)

Asthma | Eosinophilic Asthma | Asthma; Eosinophilic

United States, South Africa, United Kingdom, Korea, Republic of
Areteia Therapeutics

Recruiting

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (EXHALE-2)

Asthma | Eosinophilic Asthma | Asthma; Eosinophilic

United States, United Kingdom, Georgia, Romania, Brazil, Bulgaria, Korea, Republic of, Poland, Serbia, Argentina
Boehringer Ingelheim

Completed

Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease

Parkinson Disease
Brigham and Women's Hospital
National Institute of Mental Health (NIMH); Northwell Health; Icahn School of... and other collaborators

Completed

Targeting Cognition in Bipolar Disorder With Pramipexole (PRAM-BD)

Bipolar Disorder

United States
New York State Psychiatric Institute
National Institute of Mental Health (NIMH); Columbia University; Icahn School... and other collaborators

Completed

Imaging Dopamine Release in Depression

Major Depressive Disorder

United States
Boehringer Ingelheim

Completed

Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

Parkinson Disease
Boehringer Ingelheim

Completed

Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease

Parkinson Disease
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance

Restless Legs Syndrome

United States
Boehringer Ingelheim

Completed

A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

Restless Legs Syndrome

Germany
Boehringer Ingelheim

Completed

A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS

Restless Legs Syndrome

Denmark, Finland, Germany, Ireland, Italy, Norway, Spain, Sweden, United Kingdom
Knopp Biosciences

Completed

Open-Label, Safety and Tolerability Extension Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS) (CL211) (CL211)

Amyotrophic Lateral Sclerosis

United States
National Institute of Mental Health (NIMH)

Completed

Clinical Trial of Pramipexole in Bipolar Depression

Bipolar Disorder

United States
Region Skane
Lund University

Recruiting

Long-term Efficacy of Pramipexole in Anhedonic Depression (LONG-PRAXOL)

Depression | Anhedonia

Sweden

Search clinical trials for: Pramipexole

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations